Physician profile
James Rizzo
NPI 1750524773
$553.56
in general payments reported to CMS, 2019-2025
13 companies · $62.95 in 2025
The $62.95 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.46 · 2020: $93.76 · 2021: $36.83 · 2022: $118 · 2023: $88.61 · 2024: $69.94 · 2025: $62.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.98 | 2019-2023 | Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $124.47 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $32.54 | 2023-2024 | Stelara, Remicade, Simponi Aria |
| Siemens Medical Solutions USA, INC. | $30.71 | 2023-2024 | Rapidpoint 500e Blood Gas System, Rapidpoint 400/405/500 Wash/Waste Cartridge |
| Qol Medical, LLC | $23.28 | 2022 | |
| Novo Nordisk INC | $20.31 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $18.44 | 2022 | |
| Madrigal Pharmaceuticals | $17.46 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $14.28 | 2019 | |
| Amgen INC. | $14.27 | 2022 | |
| Ucb, INC. | $13.89 | 2019 | |
| Organon LLC | $13.09 | 2023 | Hadlima |
| Csl Behring | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.